All published articles of this journal are available on ScienceDirect.
Clinical Efficacy and Safety of Leflunomide in Egyptian Patients with Active Rheumatoid Arthritis: CLEAR Interim Results
Abd El-Monim Hilal2
Ahmed Abogamal3
Alaa Labeeb4
Amin Abdel Hamid3
Amira El Gerby2
Ayman Farouk Darwish5
Aziza Sayed Omar6
Dahlia Abdel Mohsen7
Dalia Faiez1
A M Abda8
Fatemah A. Elshabacy9
Manal Tayel10
Mohamed Elwakd11
Mohamed Mortada12
Mohsen H.Elshahaly6
Nevine Mohannad10
Raga A. Kader2
S. Z. Hassan11
Samah A. Elbakry7
Sherif Refaat13
Authors Info & Affiliations
Clinical Efficacy and Safety of Leflunomide in Egyptian Patients with Active Rheumatoid Arthritis: CLEAR Interim Results
The Open Rheumatology Journal, 2018, 12: 323-331
The last paragraph on page 327 is revised as follows:
In regards to patients receiving leflunomide as a first-line therapy, the mean ±SD CDAI total score was significantly decreased (p<0.001) from 35.40 ±16.49 at baseline visit to reach 15.04 ±9.63 after 6 weeks from treatment initiation. After additional 6 weeks, further significant decrease (p=0.028) was observed in the mean ±SD CDAI total score to reach 11.83 ±5.88.
The original paragraph provided is mentioned below:
In regards to patients receiving leflunomide as a first-line therapy, the mean ±SD CDAI total score was significantly decreased (p<0.001) from 35.40 ±16.49 at baseline visit to reach 15.04 ±9.63 after 6 weeks from treatment initiation, however after additional 6 weeks, the mean ±SD CDAI total score was insignificantly decreased (p=0.028) to be 11.83 ± 5.88.
The first paragraph on page 328 is revised as follows:
In a similar pattern, in patients receiving leflunomide as add-on therapy to other DMARDs with or without steroids, the mean ±SD CDAI total score was significantly decreased (p<0.001) from 37.09 ±14.12 at baseline visit to reach 20.42 ±9.36 after 6 weeks from treatment initiation, and it was significantly further decreased (p<0.001) to reach 15.98 ±10.32 after additional 6 weeks.
The original paragraph provided is mentioned below:
In patients receiving leflunomide as add-on therapy to other DMARDs with or without steroids, the mean ±SD CDAI total score was significantly decreased from 37.09 ±14.12 at baseline visit to reach 20.42 ±9.36 after 6 weeks from treatment initiation. Unlike patients receiving leflunomide as a first line therapy, in this group, the mean ±SD CDAI total score was significantly further decreased to reach 15.98 ±10.32 after an additional 6 weeks.
